Kymera Therapeutics Inc Asset Resilience Ratio
Kymera Therapeutics Inc asset resilience ratio. Kymera Therapeutics Inc (KYMR) has an Asset Resilience Ratio of 34.43% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Kymera Therapeutics Inc liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Kymera Therapeutics Inc (2018–2025)
Asset resilience ratio of Kymera Therapeutics Inc from 2018 to 2025. This chart shows how Kymera Therapeutics Inc's Asset Resilience Ratio has changed over time. Read KYMR total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Kymera Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see total assets of Kymera Therapeutics Inc.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $566.51 Million | 34.43% |
| Total Liquid Assets | $566.51 Million | 34.43% |
Asset Resilience Insights
- Very High Liquidity: Kymera Therapeutics Inc maintains exceptional liquid asset reserves at 34.43% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Kymera Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Kymera Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513 |
Biotechnology | 35.16% |
|
China Resources Boya Bio pharmaceutical Group Co Ltd
SHE:300294 |
Biotechnology | 23.15% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Achieve Life Sciences Inc
F:SP4P |
Biotechnology | 3.60% |
Kymera Therapeutics Inc Asset Resilience Ratio by Year (2018–2025)
Kymera Therapeutics Inc asset resilience ratio by year from 2018 to 2025. The table below shows the annual Asset Resilience Ratio data for Kymera Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 28.19% | $491.26 Million | $1.74 Billion | -9.49pp |
| 2024-12-31 | 37.68% | $368.49 Million | $978.03 Million | -8.34pp |
| 2023-12-31 | 46.01% | $264.92 Million | $575.76 Million | -10.16pp |
| 2022-12-31 | 56.17% | $338.77 Million | $603.13 Million | -8.93pp |
| 2021-12-31 | 65.10% | $394.44 Million | $605.90 Million | +10.66pp |
| 2020-12-31 | 54.44% | $265.20 Million | $487.18 Million | +40.78pp |
| 2019-12-31 | 13.66% | $15.94 Million | $116.70 Million | -- |
| 2018-12-31 | 0.00% | $0.00 | $44.23 Million | -- |
About Kymera Therapeutics Inc
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CR… Read more